TISIDB

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type II membrane protein
Domain	PF00431 CUB domain PF00057 Low-density lipoprotein receptor domain class A PF01390 SEA domain PF00089 Trypsin
Function	Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.

> Gene Ontology [ TOP ]
Biological Process	GO:0001701 in utero embryonic development GO:0001763 morphogenesis of a branching structure GO:0001838 embryonic epithelial tube formation GO:0001841 neural tube formation GO:0001843 neural tube closure GO:0001890 placenta development GO:0001892 embryonic placenta development GO:0002064 epithelial cell development GO:0003382 epithelial cell morphogenesis GO:0008544 epidermis development GO:0009913 epidermal cell differentiation GO:0014020 primary neural tube formation GO:0016331 morphogenesis of embryonic epithelium GO:0021915 neural tube development GO:0030216 keratinocyte differentiation GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0043588 skin development GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0060562 epithelial tube morphogenesis GO:0060606 tube closure GO:0060669 embryonic placenta morphogenesis GO:0060670 branching involved in labyrinthine layer morphogenesis GO:0060671 epithelial cell differentiation involved in embryonic placenta development GO:0060672 epithelial cell morphogenesis involved in placental branching GO:0060706 cell differentiation involved in embryonic placenta development GO:0060711 labyrinthine layer development GO:0060713 labyrinthine layer morphogenesis GO:0061138 morphogenesis of a branching epithelium GO:0061458 reproductive system development GO:0072175 epithelial tube formation
Molecular Function	GO:0004175 endopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0008236 serine-type peptidase activity GO:0017171 serine hydrolase activity
Cellular Component	GO:0016323 basolateral plasma membrane GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1266738: Developmental Biology R-HSA-6809371: Formation of the cornified envelope R-HSA-6805567: Keratinization

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ST14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ST14 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
22139080	Colon Adenocarcinoma	Promote immunity	Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Here, we show that intestinal epithelial-specific ablation of St14 in mice causes formation of colon adenocarcinoma with very early onset and high penetrance.

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ST14 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ST14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.205	0.715
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.273	0.858
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.568	0.576
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.586	0.295
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.929	0.724
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.144	0.963
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.367	0.515
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.568	0.618
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.044	0.974
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.106	0.413
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.575	0.78
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.045	0.701

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ST14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ST14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ST14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ST14. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ST14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ST14 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ST14 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ST14
Name	suppression of tumorigenicity 14 (colon carcinoma)
Aliases	SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ......
Chromosomal Location	11q24-q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ST14 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ST14.

ID	Name	Drug Type	Targets	#Targets
DB00013	Urokinase	Biotech	LRP2, NID1, PLAT, PLAU, PLAUR, PLG, SERPINA5, SERPINB2, SERPINE1, ......	10
DB03127	Benzamidine	Small Molecule	ATOX1, CSNK2A1, ECI1, KLK1, KLK6, PLAU, PRSS1, PRSS2, PRSS3, ST14	10

Browse ST14